Company
Sun Pharma Global
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
18
9 still marketed
Novel approvals
3
Approvals since 2021
13
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Ilumya new use Oct 29, 2026
- Vobrig approved Aug 26, 2026
- Ilumya new use Jul 16, 2026
- Ilumya new use Dec 12, 2025
- Bynfezia Pen approved Sep 27, 2024
- Ilumya new use Apr 3, 2024
- Ezallor Sprinkle new use Aug 4, 2023
- Ezallor Sprinkle new use Aug 4, 2023
- Ezallor Sprinkle new use Aug 4, 2023
- Ezallor Sprinkle new use Aug 4, 2023
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (9)
Newest FDA action first.
- Ilumya Tildrakizumab-Asmn · 2018
- Absorica Ld Isotretinoin · 2019
- Yonsa Abiraterone Acetate · 2018
- Bynfezia Pen Octreotide Acetate · 2024
- Odomzo Sonidegib Phosphate · 2015
- Drizalma Sprinkle Duloxetine Hydrochloride · 2019
- Bromsite Bromfenac Sodium · 2016
- Winlevi Clascoterone · 2020
- Cequa Cyclosporine · 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.